Kanghua Bio's Acquisition of Nameixin: A Capital-Driven Leap for Sichuan's Vaccine Industry through Shanghai-Sichuan Synergy

On January 28, Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ, hereinafter referred to as “Kanghua Biological”) announced its plan to acquire full ownership of NanoRibo (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “NanoRibo”) through subscription for capital increase and equity transfer. This transaction, occurring only months after the change in Kanghua Biological’s controlling shareholder, has drawn significant attention from the industry. The rapid acquisition of a Shanghai-based mRNA innovative technology company by this Sichuan enterprise, which established its market position with the “diploid cell rabies vaccine,” not only reflects Kanghua Biological’s strategic transformation from being “product-driven” to “platform-driven,” but also highlights a new trend wherein regional leading enterprises integrate cutting-edge technologies through cross-regional mergers and acquisitions. This case provides a reference for Sichuan and even the central and western regions of China to leverage capital strength to connect with external innovation resources and achieve industrial upgrading.

Kanghua Biologicals is the leading domestic manufacturer of human diploid cell rabies vaccines in China. This rabies vaccine is regarded as the “gold standard” product for rabies prevention and has provided Kanghua Biologicals with stable cash flow and market position over the past decade. However, the “blockbuster product” model continually faces a growth ceiling in the rapidly iterating biopharmaceutical sector.

“All successful biopharmaceutical companies must ultimately answer one question: Where is the next growth curve?” pointed out an analyst who has long followed the vaccine industry. “Especially after mRNA technology was validated during the COVID-19 pandemic, companies relying on traditional technological platforms are generally facing pressure to transform.” The management of Kanghua Biologics has recognized the limitations of a single-product portfolio, and this transaction demonstrates Kanghua Biologics’ firm commitment to innovation.

Market observers generally believe that the rapid advancement of this transaction is closely related to the change in Kanghua Biological’s controlling shareholder. In November 2025, the Shanghai Biomedical M&A Fund (hereinafter referred to as the “M&A Fund”) became the company’s controlling shareholder through Shanghai Wankexin Biology. This was not merely a financial investment but a “strategic takeover” with clear intentions of industrial integration.

“The greatest value brought by the M&A fund is providing Kangh with a clear upgrade path and execution resources,” said an investment banker close to the deal. “Their goal is clear: to transform Kangh from a ‘single-product champion’ potentially facing growth bottlenecks into a ‘platform enterprise’ equipped with diversified technology platforms and a robust product pipeline.”

NanoRibo’s core competitiveness lies in its differentiated mRNA technology platform, particularly its breakthrough lyophilization process. This technology simplifies the stringent cold-chain requirements for mRNA vaccines to standard 2–8°C storage, significantly addressing the global challenge of mRNA vaccine accessibility. Under the strategic leadership of a merger and acquisition fund, this transaction lays the foundation for Kanghua Bio to expand into broader markets in the future.

The biomedical industry faces multiple challenges, including long R&D cycles, difficulties in translating research outcomes into practical applications, slow market access, and hurdles in promotion and adoption. Sichuan Province is exploring a path that combines policy guidance with market mechanisms to drive systemic breakthroughs in the industry. On December 15, 2025, the General Office of the Sichuan Provincial People’s Government issued the “Several Policy Measures to Support the High-Quality Development of the Biomedical and Medical Device Industries in Sichuan Province,” aiming to systematically address longstanding key bottlenecks and provide institutional support for building a full-chain innovation ecosystem encompassing “introduction, digestion, absorption, and re-innovation.”

Under this policy framework, the role of specialized industrial funds has become increasingly prominent. These funds not only provide financial support to enterprises but, more importantly, leverage forward-looking industry insights, cross-regional resource networks, and mature M&A integration capabilities to help regional leading companies break through growth bottlenecks and achieve strategic upgrades. By empowering “chain-owner” enterprises, these funds can effectively drive the overall advancement of regional industrial clusters, fostering a virtuous cycle characterized by “policy guidance, capital empowerment, enterprise leadership, and ecosystem synergy.”

Taking the transaction involving Kanghua Biological Products and NanoRibo, led by a merger and acquisition fund, as an example, this deal not only facilitates the establishment of a cross-regional collaborative system characterized by “R&D in Shanghai and commercialization in Sichuan,” but also explores a viable pathway that leverages capital as a link to integrate global innovative resources and feed back into local industrial upgrading. Through this transaction, NanoRibo’s technological accumulation in the mRNA field—including core technologies such as AI-driven antigen design, LNP delivery systems, and lyophilization processes—will be deeply integrated with Kanghua Biological Products’ industrialization capabilities in Chengdu. This integration is expected to gradually establish comprehensive mRNA vaccine production capabilities in Sichuan, drive the agglomeration of upstream and downstream industry chains, and systematically enhance the technical value-added and competitiveness of the regional industry.

From policy implementation to capital infusion, and from corporate consolidation to ecosystem building, Sichuan is gradually driving the evolution of its biopharmaceutical industry from traditional “passive acceptance and translation” to “proactive integration,” reshaping local industrial competitiveness through open collaboration.

From an industrial perspective, Kangh aims to build a new structure with greater resilience and growth potential through this transaction.

First, establish a matrix of technological platforms. Upon completion of the transaction, Kanghua Bio will form a diversified technology portfolio comprising “recombinant protein VLP + polysaccharide-protein conjugate + mRNA + novel adjuvants.” This technological combination can effectively mitigate the risks associated with reliance on a single technical route and allow for the flexible selection or integration of optimal technical pathways tailored to different pathogens and market demands.

Secondly, enrich the product pipeline gradient. NanoRibo’s core R&D pipeline—the lyophilized mRNA vaccine for Respiratory Syncytial Virus (RSV)—has entered Phase I clinical trials, providing Kanghua Biology with clear growth expectations and forming a tiered structure of “current cash cow (rabies vaccine), mid-term clinical pipeline (RSV vaccine), and long-term technological reserves (mRNA platform).”

Finally, achieve regional collaborative innovation. NanoRibo will serve as Kangh’s “innovation outpost” in Shanghai, continuously leveraging local advantages in talent, technology, and information; while Chengdu will act as the “home base” for industrialization and commercialization, providing robust support for subsequent product manufacturing. Through this “dual-city linkage,” a more competitive open innovation system can be established.

Kanghua Biological’s acquisition of NanoRibo is driven by its internal imperative for self-upgrading; however, from a broader perspective, it also represents an active exploration into how regional industries can reshape their competitiveness through capital and market mechanisms in the context of open cooperation.

For Sichuan’s biopharmaceutical industry, a successful attempt by Kanghua Biologicals would have a significant demonstrative effect. Industrial leaders in the central and western regions can proactively connect with R&D and innovation resources in the eastern coastal areas through capital linkages, achieving “off-site R&D and local commercialization,” thereby finding a unique upgrade path amidst fierce regional industrial competition.

For Sichuan, in the race to become a hub for the biopharmaceutical industry, adopting a market-oriented approach of “leveraging capital to attract technology and utilizing industry to drive commercialization” can serve as an effective strategy to elevate the industry’s tier, complementing traditional efforts such as investment promotion and policy support for local leading enterprises.